Generic EPI will be more expensive to many than the brand name. The reason is that the generic Epi Most probably will not honor co-pay cards, per cheif pharmacy officer at the zcleveland clinic. Mylan is smart to do this but this could backfire beyond anything they have seen yet!
Must admit I did not see Mylan coming out with a generic for their own product! ATRS stung again I guess!
"Some of the most prominent groups — Food Allergy Research & Education (FARE), the Asthma and Allergy Foundation of America (AAFA) and Allergy & Asthma Network — have partnerships with Mylan for patient awareness campaigns and other programming. The groups are not required to disclose how much money they receive from the drug company; but Mylan, in its 2015 Social Responsibility report, lists all three as “allies.” "
Well I guess being over extended is a reason to sell, but with the stock breaking out I would have put a limit on and rode it up. I do not think this run is anywhere close to being over. Sure you may see a little consolidation but the least resistance is up!
Stockvader was not right. Check out my Saturday night post. I told you we were going to move. Just go back and look. Stockvader was following my lead and jumped on the train!
Is what issue does the FDA have with the device. I wonder if the public gets any idea from TEVA or ATRS about the device in question. If you don't find out soon with all the press we will never know.
The deal was for MYL to have time for exclusive rights, then they did the citizens petition. They fought the TEVA generic product and the FDA may have been just as guilty in preventing the generic alternative. Stated 5 letters have been sent to the FDA.
A PR would almost seem earth shattering from ATRS. Jack being accessible by phone isn't a courtesy either. It's his job, but thus far no complaints by me as far as getting to him by phone. we as investors always want more than the company will give and that's understandable, but don't let us find material information out on the web that is material to thecompany's business plan.
ATRS can find a way! What else can it be but the injector? I think it's been discussed already,but an injector for Suma would clearly not be sufficient for Epi.
I never stated I understand the FDA. Most don't. I do know they got a billion more last year to speed up approvals and it's slower than ever. I hope your reply is on the $$ b/c the "major deficiencies" remark had me slightly concerned. But the latter of 2017 is still a bummer. Seems a little more to it. Perhaps all this press on Epi will hasten things some.
So why did TEVA state that there was major deficiencies? Obviously it must be the device. How could there be major deficiencies in the dang device? Can't be that difficult to make can it? I can see differences but major deficiencies?? Isn't that close to what TEVA stated? Any thoughts?
Due to it's "marketing application"? That's what a Seekin Alpha article stated today while discussing Sen Grassley's office inquiry into Mylan's price increases on EPIPEN. What is it's "marketing application"? I guess that's just how they term a drug rejected?